H3 dopaminylation and CaMKII modulate diffuse midline glioma response to CDK9 inhibition
Rebecca L. Murdaugh, Brittany R Eberl, Rosemary U. Richard, Ena I. Campos-Hensley, Adanze N Nnyagu, W. Austin Elam, Ai-Ni Tsao, Jack R Tremblay, Ruiying Ma, Alfred K. Dei-Ampeh, Kieu Pham, Daniel C. Kraushaar, Kwanha Yu, Calla M. Olson, Akdes Serin Harmancı, , Jamie N. Anastas
This study shows that combining CDK9 inhibitors with neuropsychiatric drugs reduces diffuse midline glioma growth by altering H3 dopaminylation and CaMKII signaling.
bioRxiv · Apr 10, 2026 · PreprintCancer Biology